Physician profile
Jonathan D Andrews
NPI 1821400664
$5,850.41
in general payments reported to CMS, 2019-2025
25 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $256 · 2021: $919 · 2022: $522 · 2023: $568 · 2024: $870 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Consulting Fee: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.98 |
| Consulting Fee | $1,025.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,374.11 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $1,175.93 | 2022-2025 | Infuse, Biotrue One Day, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $722.54 | 2019-2021 | |
| Coopervision INC. | $399.80 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $302.69 | 2019-2025 | Cequa |
| Allergan, INC. | $246.39 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $209.33 | 2019-2024 | Acuvue |
| Abbvie INC. | $156.59 | 2022-2025 | Lumigan, Vuity |
| Kala Pharmaceuticals, INC. | $145.27 | 2021-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Alcon Vision LLC | $123.18 | 2020-2024 | Simbrinza, Total30 |
| Biotissue Holdings INC. | $121.88 | 2019-2025 | |
| Pfizer INC. | $119.86 | 2019-2025 | |
| Shire North American Group INC | $117.54 | 2019 | |
| Dompe US, INC. | $95.61 | 2025 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $86.80 | 2022-2025 | Tyrvaya |
| Astellas Pharma US INC | $60.51 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $58.42 | 2020-2021 | |
| Amgen INC. | $49.65 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $38.66 | 2022-2024 | Lipiflow System Activator (Disposable) |
| Thea Pharma INC. | $37.77 | 2024-2025 | Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $26.16 | 2024 | Cirrus Hd-Oct |
| Aerie Pharmaceuticals, INC. | $20.09 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.